Annual Report 2021/22

Over the course of another year marked by the shadows of the pandemic and its ramifications, we have all had to find entirely new solutions to deal with the challenges brought by the coronavirus. And once again, the outstanding ability to combine biotechnology research with process engineering expertise has proved to be a key factor here.

Highlights in the area of health

Just like the vaccine manufacturers, we at Fraunhofer IGB have put our know-how to work and developed tools to address these new challenges. For example, in the Healthy Air Initiative of the state of Baden-Württemberg, we helped to develop new methods for detecting viruses in aerosols. We have also conducted extensive research to find ways of increasing our PCR testing capacity to meet demand. One promising development is a procedure for detecting SARS-CoV-2 based on the high-throughput sequencing method developed at the IGB.

CO2 as raw material

However, we have more on our plate than just the pandemic, since the issue of climate change also calls for fast progress in technology. In a wide range of projects – such as CO2EXIDE – we are investigating ways of using CO2 as raw material for innovative conversion processes and to manufacture sustainable products. One of these novel solutions, which was developed under the collaboration program between Fraunhofer and Max Planck Society, brought our vision of combining biology and engineering to life in a particularly impressive way. In this project, the team in Straubing and their partners have successfully fixed CO2 in a redox-active hydrogel for the first time, by means of electro-biocatalytic reduction.

Hydrogen Lab Leuna

One of the outstanding events of the year was the launch of the Hydrogen Lab Leuna, an electrolysis plant that we constructed in collaboration with the Fraunhofer Institute for Microstructure of Materials and Systems IMWS (headquartered at Fraunhofer IWES). Now, for the first time, the Fraunhofer Center for Chemical-Biotechnological Processes CBP, our institute branch in Leuna, will be able to test the production of chemical components from green hydrogen under real life conditions of fluctuating energy generation in a chemical park.

Our research highlights

 

Health

 

  • Diagnostics
  • Drug development
    • Human test systems, immunoreceptor assays and production cell lines
    • Virus engineering
    • Drug Delivery and Release
 

Sustainable Chemistry

 

  • Fine and specialty chemicals
  • Biopolymers and biobased polymers
  • Food and cosmetics
  • Power-to-X and chemical CO2 recycling
 

Environment

 

  • Smart infrastructures
  • Treatment of process water, wastewater and sludge
  • Efficient production of biogas
  • Secondary resources, raw materials and water reuse

Highlights 2021

  • Dialogue with the public
  • Brief interview: Chemical analytics
  • Successful research transfer with Fraunhofer IGB spin-off
    Variolytics
  • ...

 

 

Equal opportunities

We make every effort to structure our daily working life in such a way as to promote equal opportunities, which is demonstrated in the new initiatives we have established for employees, for example.

 

Brief interview: Chemical analytics

Reliable analytics is the basis for research and product development.

Browse directly through the annual report ...

We research on your behalf

 

Spectrum of services

Fraunhofer IGB develops, realizes and optimizes processes, products and plants as well as new technologies – from the feasibility study to implementation.

 

Cooperation models

From research contracts and collaborative research projects to licensing and strategic partnerships, many ways of working together are possible.

Annual Reports of the Fraunhofer IGB

The annual reports of the previous years are available for download. We would also be pleased to send you a printed report. Subscribe to our newsletter to stay in touch with us.

 

Archive Annual Reports

The annual reports of the previous years can be found on the following page:

Newsletter Subscription

Subscribe to our regular newsletter with up-to-date news from our research.